• **Name:** David Tai

• **Current Position & Affiliation:** Clinical Associate Professor, Duke-NUS Medical School
Senior Consultant Medical Oncologist, National Cancer Centre Singapore

• **Country:** Singapore

• **Educational Background:**

Degree/year	Institution	Discipline
MBBS/2004	National University of Singapore	Medicine and Surgery
MRCP/2007	Royal College of Physicians	Internal Medicine
Specialist Accreditation for Medical Oncology/2011	Academy of Medicine, Singapore	Medical Oncology

• **Professional Experience:**

- Senior Consultant Medical Oncology
- Clinical Associate Professor – Duke NUS

• **Professional Organizations:**

- Division of Medical Oncology, National Cancer Centre Singapore, 11, Hospital Crescent, S 169610

• **Main Scientific Publications:**

1. Clinicopathologic characteristics and survival of patients with gastroenteropancreatic neuroendocrine neoplasm (GEPNEN) in a multi-ethnic Asian institution Neuroendocrinology. 2018 Nov 6. doi: 10.1159/000495140.
2. Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms.
   Surgery. 2018 Dec 14. pii: S0039-6060(18)30747-5. doi: 10.1016/j.surg.2018.10.031.
3. Validation and comparison between current prognostication systems for pancreatic neuroendocrine neoplasms: A single-institution experience with 176 patients..Surgery. 2017 May;161(5):1235-1245.
4. A Phase II Single Arm, Single Centre Trial of Y90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular Carcinoma– CA 209-678. Lancet Gastroenterology and Hepatology 2021.
5. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
   Hepatol Int. 2021 Jul 31.
6. Efficacy and Tolerability of Novel Regimen of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
   Journal of Clinical Oncol 2021 Jul 22:JCO2003555.

7. Non-Terminally Exhausted Tumor-Resident Memory HBV-specific T Cell Responses Correlate with Relapse-Free Survival in Hepatocellular Carcinoma
Immunity. 2021 Aug 10;54(8):1825-1840
8. Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma.
Liver Cancer. 2021 Jun;10(3):224-239.
9. Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit.
ESMO Open. 2021 Apr 19;6(3):100129.
10. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.
Liver Cancer. 2021 Apr;10(2):107-114.
11. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
J Immunother Cancer. 2020 Aug;8(2): e000987.
12. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
Front Immunol. 2020 Sep 30;11:568759
13. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
Asia Pac J Clin Oncol. 2020 Sep 1.
14. Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients with Intermediate and Advanced/Relapsed Hepatocellular Carcinoma: A TOS-ESMO Initiative Endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSOPublished online 06 JAN 2020 - Ann Oncol (2020).
15. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Predictive Biomarkers..
Cancers (Basel) 2019 Dec 3;11 (12).
16. Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma.
Surgery. 2018 May;163(5):1008-1013.
17. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016 Sep 13.
18. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). .Ann Oncol. 2016 Dec;27(12):2210-2215
19. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer. 2016 Apr;5(2):97-106.
20. Current role of selective internal radiation with yttrium-90 in liver tumors.Future Oncol. 2016 May;12(9):1193-204.